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Available online 7 June 2016Background. Early-stage chronic kidney disease (CKD), a marker of cardiovascular risk, is susceptible to ther-
apeutic intervention but need further study in populations with low incidence of coronary heart disease (CHD).
Incorporating glomerular ﬁltration rate (GFR) could improve cardiovascular risk prediction in these patients.
Objective. To determine if decreased GFR is associated with increased risk of cardiovascular morbidity and
all-cause mortality and to analyse GFR effect on cardiovascular risk prediction in a population with low CHD
incidence.
Methods. Retrospective, observational, population-based study of 1,081,865 adults (35–74 years old). Main
exposure variable: GFR. Outcomes: CHD, cerebrovascular disease, cardiovascular diseases, all-cause mortality.
Association between GFR categories of CKD (G1–G5) and outcomes was tested with Cox survival models. G1
was deﬁned as the reference category. Predictive value of GFR was evaluated by integrated discrimination im-
provement (IDI) and net reclassiﬁcation improvement (NRI) indices.
Results. Beginning at stage-3a CKD, increased riskwas observed for coronary (HR 1.27 (95%CI 1.14–1.43)), ce-
rebrovascular (HR 1.19 (95%CI 1.06–1.34)), cardiovascular (HR 1.23 (95%CI 1.13–1.34)) and all-cause mortality
risk (HR 1.17 (95%CI 1.07–1.27)). GFR did not increase discrimination and reclassiﬁcation indices signiﬁcantly
for any outcome.
Conclusion. In general population with low CHD incidence and stage-3 CKD, impaired GFR was associated
with increased risk of all cardiovascular diseases studied and all-cause mortality, but adding GFR values did
not improve cardiovascular risk calculation. Despite a four-fold higher rate of CHD incidence at GFR G3a com-
pared to G1, this represents moderate cardiovascular risk in our context.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Electronic medical records1. Introduction
Cardiovascular diseases are the leading cause of mortality and mor-
bidity worldwide. They account for 30% of global mortality and are ex-
pected to remain the leading cause of death in coming years (World
Health Organization, 2011) (Mathers & Loncar, 2006). Althoughary Care Research (IDIAP Jordi
titute of Health (ICS), Carrer
s).
. This is an open access article undersouthern Europe has one of the lowest cardiovascular mortality and
morbidity rates in the European Union (Nichols et al., 2012), these dis-
eases constitute one of the main morbidity impacts, being the second
leading cause of expected years of life lost and theﬁrst cause of hospital-
ization (INE, 2014) (Gènova-Maleras et al., 2011). Therefore, prevention
of cardiovascular diseases remains a priority of health policies and bio-
medical research in this population.
Currently, one of the main disease prevention strategies is to inter-
vene in the high-risk healthy population. Treating cardiovascular risk
factors decreases the risk of cardiovascular diseases (Graham et al.,
2007). Although risk functions are used to identify those individuals at
higher risk, the functions are not sufﬁciently accurate (Marrugat et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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functions by considering new risk factors.
Recently, several studies have shown that impaired renal function,
even at very early stages, is independently associated with the occur-
rence of cardiovascular events (Go et al., 2004) (Brugts et al., 2005)
(Meisinger et al., 2006) (Van Biesen et al., 2007) (Di Angelantonio et
al., 2007) (Astor et al., 2008) (Cirillo et al., 2008) (Matsushita et al.,
2010b). Thus, current clinical practice guidelines recommendmaximiz-
ing cardiovascular prevention in patients with chronic kidney disease
(CKD) at all stages (Group KDIGO (KDIGO) CW, 2013) (Bover-Sanjuán
et al., 2014) (Rabar et al., 2014 Jan). Moreover, recent research has sug-
gested thatmarkers of CKDwould help to improve the prediction of car-
diovascular events in addition to traditional cardiovascular risk factors
in populations with high cardiovascular risk (Di Angelantonio et al.,
2010) (Shara et al., 2011) (Smink et al., 2012). Nonetheless, studies on
the role of impaired renal function as a cardiovascular risk are mainly
carried out in populations with high incidence of CHD. In this study,
we aimed to examine the potential capacity of CKD, as deﬁned by glo-
merular ﬁltration rate (GFR), to improve the prediction of cardiovascu-
lar events and all-cause mortality in a general population with low
incidence of CHD (Marrugat et al., 2011).
2. Materials and methods
2.1. Study design
2.1.1. Retrospective cohort study
2.1.1.1. Data source.Datawere obtained from the Information System for
the Development of Research in Primary Care (SIDIAP). This clinical da-
tabase contains the anonymized, longitudinal medical records of nearly
ﬁvemillion patients, comprising around 80% of the Catalan and 10.2% of
the Spanish populations (Bolíbar et al., 2012). The records contain de-
mographic information, clinical diagnoses (International Classiﬁcation
of Diseases 10th revision [ICD-10]), referral and hospital discharge in-
formation (International Classiﬁcation of Diseases 9th revision [ICD-
9]), laboratory tests and treatments (drug prescriptions and drugs in-
voiced at the community pharmacy). General practitioners follow regu-
lated protocols on data recording, and are assessed for its completeness
and continuity: the records qualiﬁed as “up to standard” for biomedical
research are called SIDIAPQ (García-Gil et al., 2011) andwere used in the
present study. The quality of SIDIAP data has been previously docu-
mented, and the database has beenwidely used to study the epidemiol-
ogy of a number of health outcomes (Ramos et al., 2012) (Prieto-
Alhambra et al., 2014) (Vinagre et al., 2012) (Simó et al., 2013)
(Violán et al., 2013). This study received its approval from the research
ethics committee of IDIAP Jordi Gol.
2.2. Participants
In total, 1,081,865 people aged 35 to 74 years without previous his-
tory of cardiovascular disease, deﬁned as myocardial infarction (MI),
angina pectoris, stroke, transient ischemic attack (TIA), or peripheral ar-
terial disease (PAD), and who were registered with a primary health
care centre providing data to SIDIAPQ between January 2008 and De-
cember 2013, were eligible for inclusion in this study.
2.2.1. Follow-up and outcomes
The six-year study period was January 2008 to December 2013. The
follow-up period was deﬁned from January 2009 to 2013. For individ-
uals with a creatinine measurement, we used the ﬁrst record as an
index date; without creatinine data, January 2009 was the index date.
Baseline period was deﬁned as 1-year before the index date.
Patients were censored at the earliest date of the diagnosis of inter-
est, at transfer out of the primary health care centre or at the study enddate (31 December, 2013). Time to ﬁrst event was considered for all
analyses.
Vascular diseaseswere identiﬁed in follow-up from relevant SIDIAPQ
codes in the patients' clinical ﬁles, both primary care and hospital dis-
charge records. The cardiovascular codes have been previously validat-
ed in SIDIAP (Ramos et al., 2012).
The primary outcomes were coronary heart disease, a composite
of myocardial infarction (MI) and angina; cerebrovascular disease,
consisting of stroke and transient ischemic attack (TIA); cardiovascular
diseases, a composite of MI, angina, stroke and TIA; and ﬁnally, all-cause
mortality.
The presence of vascular disease was deﬁned according to the fol-
lowing criteria:
• Coronary heart disease: MI (ICD-10 codes: I21-I23 and subcategories;
ICD-9 code: 410) and angina (ICD-10 codes: I20 and subcategories;
ICD-9: 411.1, 413); and
• Cerebrovascular disease: stroke (ICD-10 codes: I61-I64 and subcate-
gories; ICD-9: 433, except for non-occlusive disease, so 433.00,
433.10, 433.20, 433.30, 433.80, 433.82, 433.90, 434.00, 434.10,
434.11, 434.90) and TIA (ICD-10 codes: G45-G46; ICD-9 code: 435).
2.2.2. Main exposure
• Standardized creatinine was used for CKD-Epidemiology Collabora-
tion (CKD-EPI) calculations, according to “Kidney disease: Improving
global outcomes” (KDIGO) guidelines (Group KDIGO (KDIGO) CW,
2013) (mg/dl).
o Glomerular ﬁltration rate (GFR) was calculated by CKD-EPI equation
(Levey et al., 2009).
o GFR categories in CKD were deﬁned by the KDIGO guideline (Group
KDIGO (KDIGO) CW, 2013):
▪ G1 ≥ 90 ml/min/1.73 m2
▪ G2 60–89 ml/min/1.73 m2
▪ G3a 45–59 ml/min/1.73 m2
▪ G3b 30–44 ml/min/1.73 m2
▪ G4 15–29 ml/min/1.73 m2
▪ G5 b 15 ml/min/1.73 m2.2.2.3. Covariates
A set of variableswere deﬁned a priori and obtained from SIDIAPQ at
baseline:
• Age
• Sex
• Hypertension (yes/no) or record of antihypertensive drug invoicing
• Dyslipidaemia (yes/no)
• Smoking (yes/no)
• Obesity (yes/no) deﬁned as BMI N 30 kg/m2
• Diabetes (yes/no) or record of antidiabetic drug invoicing
• Systolic blood pressure (SBP) (mm Hg)
• Diastolic blood pressure (DBP) (mm Hg)
• Laboratory tests: fasting glucose, total cholesterol, high-density lipo-
protein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol,
triglycerides
• Body mass index (BMI) (kg/m2)
• Drug use: antihypertensive agents, antidiabetic agents, or statins and
other lipid-lowering drugs
• Ten-year CHD risk, estimated using the Framingham function adapted
and validated in the Spanish population by the REGICOR study
(Marrugat et al., 2007).
2.3. Statistical analysis
Categorical variables are presented as percentages and continuous
variables as mean (standard deviation) and 95% conﬁdence intervals
(95%CI) were calculated when required.
202 M. García-Gil et al. / Preventive Medicine 89 (2016) 200–206Missing data were imputed using 20 multiple imputations by
chained equations (White et al., 2011) to replace baseline missing
values in the logarithmof total cholesterol, HDL cholesterol, LDL choles-
terol, triglycerides, glucose, systolic blood pressure and the difference
between systolic and diastolic blood pressure, weight, height and creat-
inine. We also performed a case-complete sensitivity analysis to assess
the proper functioning of the multiple imputation process. The associa-
tion between GFR and cardiovascular events/all-cause mortality was
assessed by multivariate Cox survival models adjusted for age, sex,
smoking habit, diabetes, blood pressure levels, total cholesterol and,
HDL cholesterol levels. GFR ≥ 90ml/min/1.73m2 (category G1) was de-
ﬁned as the reference value. We tested the proportional hazards as-
sumption and analysed linearity between GFR and all outcomes.
We calculated Harrell's C index to assess the discrimination for cen-
sored time-to-event data and reclassiﬁcation measures to assess the
prediction of risk for all outcomes with GFR: Integrated discrimination
improvement index (IDI) in continuous form and net reclassiﬁcation
improvement index (NRI) calculated at ﬁve years. Bootstrap estimation
was performed to calculate 95% conﬁdence intervals of the NRI.
Models for CHD and cardiovascular disease without angina were
also built to assess the possible diluting effect of angina. Sensitivity anal-
ysis with models deﬁning CKD only as GFR b 60 ml/min/1.73 m2 were
also performed.
We used R-package (version 3.2) and the survidinri and nricens
packages (Team R Core, 2014) for statistical analyses, with two-sided
tests and p b 0.05.
3. Results
3.1. Baseline results
In total, 1,081,865 primary care patients aged 35–74 years were in-
cluded between 2008 and 2013. In more than 75% of patients, follow-
up was 5 years.
Table 1 presents overall baseline characteristics of the study popula-
tion according to GFR categories of CKD and the percentage of missing
values for the imputed variables. The percentage of missing values for
weight, height and glucose were 44.7%, 46.1%, and 53.6%, respectively.
These variables are not presented in Table 1 but were used in theTable 1
Baseline characteristics of the study population by glomerular ﬁltration rate categories.
Glomerular ﬁltration
Characteristics Total % missing G1
Populationa 1,081,865 (100%) – 703,242 (65.00%)
Ageb (years) 49.53 (11.6) – 45.90 (9.7)
Sexa (women) 550,712 (50.9%) – 364,001 (51.8%)
Hypertensiona 226,901 (21.0%) – 94,823 (13.5%)
Dyslipidemiaa 219,971 (20.3%) – 108,332 (15.4%)
Smokinga 371,229 (34.3%) – 254,443 (36.2%)
Obesitya 330,525 (30.6%) – 198,697 (28.3%)
Diabetesa 74,725 (6.9%) – 35,916 (5.1%)
Systolic blood pressure (mmHg)b 127.55 (16.6) 64.1% 126.10 (16.3)
Diastolic blood pressure (mmHg)b 77.23 (9.9) 64.5% 76.97 (10.0)
Cholesterol (mg/dL)b 205.56 (38.5) 54.3% 203.21 (38.3)
HDL cholesterol (mg/dL)b 54.75 (14.8) 66.6% 54.59 (14.8)
LDL cholesterol (mg/dL)b 127.15 (34.1) 67.3% 125.49 (33.9)
Triglycerides (mg/dL)b 121.50 (78.9) 64.9% 118.77 (79.2)
Body mass index (kg/m2)b 27.48 (5.0) 47.7% 27.15 (5.0)
Statinsc 100,291 (9.3%) – 39,443 (5.6%)
Aspirinc 29,223 (2.7%) – 10,681 (1.5%)
Antihypertensivesc 169,546 (15.7%) – 64,129 (9.1%)
Antidiabetic agentsc 49,143 (4.5%) – 22,610 (3.2%)
Creatinine (mg/dL)b 0.83 (0.2) 66.4% 0.75 (0.1)
GFR (ml/min/1.73 m2)b 95.08 (16.1) – 104.60 (8.9)
10-year coronary risk 3.14 (3.2) 2.54%
a N and %.
b Mean and standard deviation.
c Drug consumption, N and %.multiple imputation process. The mean age was 49.5 (11.6) years, and
women constituted 51% of the cohort. Diabetes was present in about
7% of participants, obesity in 31%, hypercholesterolemia in 20% and hy-
pertension in 21%; about one third were smokers. Mean 10-year coro-
nary risk was 3%. The most frequently prescribed medications were
antihypertensive agents (15.7%), followed by statins (9.3%), antidiabetic
agents (4.5%), and aspirin (2.7%). In general, the proportion of all these
factors increased as GFR decreased, apart from patients in GFR category
G5. Mean GFR was 95 ml/min/1.73 m2 (SD: 16.1). However, the distri-
bution was skewed and 1,057,283 patients in GFR categories G1 and
G2 accounted for nearly 97% of the total population. There were
24,582 (2.2%) participants with a GFR below 60 ml/min/1.73 m2;
20,465 (83%) of them belonged to GFR category G3a.
The proportion of missing data in the variables considered for the
risk function prediction and a comparison of the complete-case dataset
and imputed dataset are shown in the Supplementary ﬁle (Tables S1–
S3). Mean values of these variables remained similar after multiple
imputations.
3.2. Outcome incidences
Within the period 2009–2013, overall unadjusted incidences per
100,000 persons-year at risk (PYAR) of coronary heart disease, cerebro-
vascular disease, cardiovascular diseases and all-cause mortality were
205.1 (95%CI 201.1–209.1), 182.0 (95%CI 178.2–185.7), 381.2 (95%CI
375.7–386.7) and 264.0 (95%CI 259.4–268.5), respectively. The risks in-
creased with stage of renal function, except that individuals in stage 5
had a lower incidence of stroke (Table 2).
3.3. Multivariate associations
Adjusted hazard ratios signiﬁcantly differed between GFR categories
(CKD) for coronary heart disease, cerebrovascular disease, cardiovascu-
lar diseases and all-cause mortality (Fig. 1). Patients with lower GFR
were more likely to have higher incidence of coronary and cerebrovas-
cular events and higher all-cause mortality. Hazards ratios ranged from
1.07 (95%CI 1.01–1.14) to 3.02 (95%CI 1.51–6.07) for coronary heart dis-
ease, 1.02 (95%CI 0.96–1.09) to 2.06 (95%CI 0.92–4.59) for cerebrovas-
cular disease, 1.05 (95%CI 1.00–1.09) to 2.58 (95% 1.52–4.36) forrate categories in chronic kidney disease
G2 G3a G3b G4 G5
354,041 (32.73%) 20,465 (1.89%) 3447 (0.32%) 475 (0.04%) 195 (0.02%)
55.71 (11.9) 63.87 (9.7) 66.14 (8.5) 64.75 (10.0) 60.37 (11.1)
173,954 (49.1%) 10,740 (52.5%) 1689 (49.0%) 240 (50.5%) 90 (46.2%)
115,799 (32.7%) 12,679 (62.0%) 3006 (87.2%) 425 (89.6%) 167 (85.6%)
100,944 (28.5%) 8625 (42.2%) 1749 (50.8%) 232 (49.0%) 87 (44.6%)
109,937 (31.1%) 5519 (27.0%) 1094 (31.7%) 161 (33.9%) 73 (37.4%)
120,980 (34.2%) 8803 (43.0%) 1730 (50.2%) 242 (50.9%) 72 (37.1%)
33,986 (9.6%) 3600 (17.6%) 1019 (29.6%) 147 (31.0%) 54 (27.7%)
130.01 (16.7) 133.51 (17.1) 135.35 (18.3) 135.51 (19.3) 136.23 (25.0)
77.72 (9.8) 77.77 (9.8) 77.39 (10.5) 76.65 (11.1) 77.65 (13.5)
210.00 (38.5) 210.23 (39.2) 202.81 (40.7) 198.32 (46.1) 179.83 (47.6)
55.13 (14.9) 54.59 (14.8) 51.51 (14.3) 48.95 (13.5) 48.69 (14.1)
130.39 (34.2) 129.25 (34.7) 121.61 (35.0) 118.19 (37.6) 105.38 (38.2)
125.72 (77.5) 135.79 (80.5) 152.63 (91.7) 163.32 (110.0) 143.93 (86.8)
28.00 (4.9) 29.09 (5.1) 29.81 (5.2) 29.89 (5.6) 28.30 (4.9)
53,259 (15.0%) 5869 (28.7%) 1411 (40.9%) 222 (46.7%) 85 (43.6%)
15,881 (4.5%) 1987 (9.7%) 557 (16.2%) 83 (17.5%) 32 (16.4%)
91,452 (25.8%) 10,828 (52.9%) 2642 (76.7%) 367 (77.4%) 126 (64.6%)
23,104 (6.5%) 2552 (12.5%) 744 (21.6%) 97 (20.6%) 34 (17.4%)
0.95 (0.2) 1.21 (0.2) 1.60 (0.3) 2.42 (0.6) 6.33 (2.6)
79.17 (7.8) 54.83 (4.0) 39.38 (4.1) 24.61 (4.3) 9.06 (3.4)
4.14% 5.58% 6.78% 6.68% 5.39%
Table 2
Number of events and incidence rates per 100,000 participants/year (95% CI) for each outcome by GFR category in chronic kidney disease.
GFR categories in chronic kidney disease
Outcomes Total events
Incidence/100,000/yr (95% CI)
G1 G2 G3a G3b G4 G5
Coronary heart diseasea 10,031 4445 4924 517 123 15 8
205.1 141.2 301.7 555.3 833.3 820.8 1206.3
(201.1–209.1) (136.4–146.0) (292.1–311.4) (498.8–611.7) (655.7–1010.8) (380.2–1261.5) (370.4–2042.3)
Cerebrovascular diseaseb 8900 3522 4697 531 124 21 6
182.0 111.8 287.7 570.0 845.1 1126.3 900.1
(178.2–185.7) (107.6–116.1) (278.3–297.1) (510.9–629.1) (675.3–1014.8) (606.5–1646.0) (179.9–1620.3)
Cardiovascular diseasec 18,634 7871 9452 1023 238 36 14
381.2 250.1 579.5 1101.3 1619.5 1940 2113.3
(375.7–386.7) (243.8–256.4) (566.2–592.9) (1016.4–1186.3) (1385.4–1853.6) (1277.6–2602.6) (1006.3–3220.2)
All-cause mortality 12,917 5692 6135 728 276 62 24
264.0 180.7 375.6 780.8 1874.3 3349.9 3596.7
(259.4–268.5) (175.2–186.2) (364.1–387.2) (715.8–845.8) (1623.9–2124.7) (2464.8–4235.0) (2157.7–5035.7)
Values in each cell: 1. number of events. 2 incidence rate per 100,000 participants. 3.95% CI (conﬁdence interval) of the incidence rate.
a Acute myocardial infarction and angina.
b Stroke and transient ischemic attack.
c Myocardial infarction, angina, stroke and transient ischemic attack.
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7.86) for all-cause mortality. From the GFR category G3a upwards, the
increase in riskwas signiﬁcant for all outcomes –, coronary heart disease
(HR 1.27 (95%CI 1.14–1.43)), cerebrovascular disease (HR 1.19 (95%CI
1.06–1.34)), cardiovascular diseases (HR 1.23(95%CI 1.13–1.34)), and
all-causemortality (HR 1.17 (95%CI 1.07–1.27)).Modelswithout angina
showed no relevant differences compared to the models including this
outcome (data not shown).Fig. 1. Multivariate Cox survival models. Models adjusted for: age, sex, smoking habit, diab
value b 0.002 in all outcomes.3.4. Discrimination and reclassiﬁcationmeasures with glomerular ﬁltration
rate
GFR did not increase theNRI index signiﬁcantly in any outcome: cor-
onary heart disease (NRI 0.3%, 95%CI−0.45–1.11), cerebrovascular dis-
ease (NRI 0.2%, 95%CI −0.63–1.04), cardiovascular diseases (NRI
−0.005%, 95%CI −0.46–0.45) and all-cause mortality (NRI 0.03%,etes, blood pressure levels, total cholesterol and HDL cholesterol levels. Trend test p-
204 M. García-Gil et al. / Preventive Medicine 89 (2016) 200–20695%CI −0.00–0.94 (Table 3). A sensitivity analysis that deﬁned CKD
only as GFR b 60 ml/min/1.73 m2 instead of the GFR categories of CKD
stages produced similar results (data not shown).4. Discussion
The present study in a general population without previous cardio-
vascular disease and with low incidence of coronary disease shows
that impaired levels of GFR are associated with an increased incidence
of cardiovascular events and all-cause mortality. Risk of suffering either
coronary or cerebrovascular events was clinically signiﬁcant higher be-
ginning at GFR category G3a, the level that deﬁnes CKD onset. However,
including GFR did not improve the predictive ability of cardiovascular
risk functions.
In relation to coronary events, previous studies in populations with
low cardiovascular risk showed similar results. Cirillo et al. (Cirillo et
al., 2008) found an increased cardiovascular risk with an impaired GFR
from GFR category G3a upwards. As expected, themagnitude of this as-
sociation was lower than that found in populations with higher cardio-
vascular risk (Di Angelantonio et al., 2010).
Our ﬁndings on cerebrovascular events are consistent with a recent
meta-analysis (Lee et al., 2010) examining the association between im-
paired GFR (G3a and higher) and the incidence of cerebrovascular
disease.
For all-cause mortality, our ﬁndings suggested signiﬁcantly in-
creased risk for patients in GFR category G3a, which was also reported
by Matsushita et al. (Matsushita et al., 2010b). However, they reported
a greater magnitude of the association. In our study, GFR category G2
was more likely to be protective for all-cause mortality. It is possible,
however, that some individuals might have been misclassiﬁed as G2
(N60 ml/min/1.73 m2) and the ﬁnding may be not reliable due to the
CKD-EPI equation's lack of precision in GFR estimation (Levey et al.,
2009; Matsushita et al., 2010a).
Most of the current international guidelines consider patients with
CKD to be at high risk of cardiovascular events and death, independent
of their estimated cardiovascular risk and, consequently, recommend
reducing the goals for other cardiovascular risk factors when evaluating
these individuals (Perk et al., 2012; Group KDIGO (KDIGO) CW, 2013;
(Rabar et al., 2014). Nonetheless, this recommendation would apply
only in populations with an observed incidence of CHD higher than
the risk thresholds for high coronary risk, as deﬁned in international
guidelines.
Thus, recommendations of these guidelines may be adequate in
countries with high incidence of CHD or cardiovascular mortality
(Shara et al., 2011; Astor et al., 2008; Hallan et al., 2006), whereas it
may be less suitable in low-incidence populations (Cirillo et al., 2008;Table 3
Measures of discrimination and reclassiﬁcation for each model.
Discrimin
Outcomes C-index model 1 (95% CI)a C-index m
Coronary heart diseasec 0.8003
(0.7945–0.8061)
0.8007
(0.7949–
Cerebrovascular diseased 0.8070
(0.8010–0.8131)
0.8074
(0.8013–
Cardiovascular diseasee 0.7975
(0.7933–0.8017)
0.7979
(0.7937–
All-cause mortality 0.7866
(0.7816–0.7916)
0.7878
(0.7824–
CI: Conﬁdence interval.
a Model 1: Adjusted for age, sex, smoking habit, diabetes, blood pressure levels, total choles
b Model 2: Model 1 plus glomerular ﬁltration rate.
c Acute myocardial infarction and angina.
d Stroke and transient ischemic attack.
e Myocardial infarction, angina, stroke and transient ischemic attack.Wen et al., 2008; Nakayama et al., 2007) and, particularly, in patients
with moderate renal impairment.
In our study, despite a four-fold higher incidence rate of CHD at GFR
category G3a, compared to G1, it remained close to 0.55% annually (i.e.,
5.5% at 10 years), which is a moderate level of cardiovascular risk. Addi-
tionally, moderate renal impairment (GFR category G3a) was observed
in more than 80% of patients with GFR below 60ml/min/1.73m2. Final-
ly, we observed that the classical cardiovascular risk factors accounted
for most of the individual CHD risk in GFR category G3a, compared to
G1, as only 27% was associated to GFR ((unadjusted HR 3.95 (95% CI:
3.55–4.41), adjusted HR 1.27 (95% CI: 1.14–1.43)).
Thus, to consider all CKD patients at high cardiovascular risk, espe-
cially patients with moderate CKD, may result in an overestimation of
their risk and could lead to unnecessary interventions. Individuals
from a population with a low incidence of CHD and with impaired
GFR should not automatically be considered at high cardiovascular risk.
Incorporating information on renal impairment into risk assessment
tools was one possible option to improve the assessment of cardiovas-
cular risk in patients with CKD. As we observed, however, this change
did not signiﬁcantly improve risk function performance. This ﬁnding is
consistent with previous literature (Di Angelantonio et al., 2010; Shara
et al., 2011; Smink et al., 2012; Donfrancesco et al., 2013; Puddu et al.,
2014). Therefore, the main concern remains ﬁnding the best way to
deal with the excess of risk in this population in the clinical practice.
One strategy could be to take GFR information into account in individ-
uals with borderline (Regicor 8–9% or Score 3–4%) cardiovascular risk
(Conroy et al., 2003) in order to reclassify them more accurately when
assessing their individual risk. Some prevention guidelines (Perk et al.,
2012) recommend this strategy to account for other risk factors, such
as sedentary behaviour or family history of premature cardiovascular
disease, as a part of the decision-making process in clinical practice.
4.1. Strengths and limitations
Amajor strength of this study is that it was based on validated, high-
quality, electronicmedical records that provided a large sample size and
reﬂected real-life conditions. Instead of excluding individuals with
missing data, we chose to usemultiple imputation of themissing values
for continuous variables. This method intends to avoid selection bias if
the population with missing data somehow differs from those with
complete data (White et al., 2011).
Albuminuria and uric acid are also predictors of all-cause and cardio-
vascular mortality and atherosclerosis (Puddu et al., 2014; Sambon et
al., 2012; Krishnan et al., 2011). However, we were unable to fully ex-
amine the renal function because we could not get albuminuria and
uric acid data. These screening tests are performed only in certain clin-
ical conditions such as diabetes or hypertension. Moreover, data fromation and reclassiﬁcation measures
odel 2 (95% CI)b IDI (%) (95% CI) NRI
(%) (95% CI)
0.8065)
0.0201
(−0.0067–0.0469)
0.3289
(−0.4590–1.1165)
0.8134)
0.0090
(−0.0071–0.0251)
0.2042
(−0.6342–1.0426)
0.8021)
0.0269
(0.0005–0.0532)
−0.0052
(−0.4609–0.4506)
0.7924)
0.1502
(0.0146–0.2859)
0.0390
(−0.0087–0.9441)
terol and HDL cholesterol.
205M. García-Gil et al. / Preventive Medicine 89 (2016) 200–206other more accurate methods for estimating GFR, such as Cystatin C
measurement (Coll et al., 2000) were not available. However, our aim
was to ﬁnd a kidney function marker for improving cardiovascular risk
assessment in the general population, and these methods are not easily
accessible in primary care. Therefore, GFR estimated by the CKD-EPI
equation is a more suitable measurement for this purpose than albu-
minuria or GFRmeasured byCystatin C.We could not use a race variable
to calculate GFR; however, Caucasian race is predominant in our popu-
lation, and thuswe assume that this limitation does notmodify ourﬁnd-
ings. We were also unable to analyse the effect of renal function on
cardiovascular death, as cause of death information is not available in
the SIDIAP database. Although GFR estimation is not recommended in
pregnantwomen, individualswith acute renal failure, or type 1 diabetes
(Perrone et al., 1992; Rule & Teo, 2009), these individuals were not ex-
cluded from our study. Nonetheless, it is unlikely that their GFR estima-
tion had a major impact on our results as these individuals represented
less than 1% of the total population. The relationship between GFR and
the outcomes was non-linear. Although arbitrary categorisations (e.g.,
quartiles, dichotomisation)maynot accurately describe non-linear rela-
tionships, categories deﬁned according to KDIGO guidelines have been
validated/are appropriate for use in CVD risk management (Group
KDIGO (KDIGO) CW, 2013).
5. Conclusion
In general populationwith low incidence of CHDandCKD stage 3aor
higher, impaired GFR implies an increased risk of cardiovascular dis-
eases, both coronary and cerebrovascular, as well as an increased risk
of all-cause mortality. However, the addition of GFR in a cardiovascular
risk model did not improve prediction. Despite a four-fold higher inci-
dence rate of CHD at GFR category G3a, compared to G1, it remained
close to 0.55% annually (i.e., 5.5% at 10 years), which is a moderate car-
diovascular risk in our context. Thus, individuals with impaired GFR
froma populationwith a low incidence of CHD should not automatically
be considered at high cardiovascular risk.
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